NetraMark Holdings Inc C.AIAI

Alternate Symbol(s): AINMF

Healthcare Medical Devices

NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.

CSE:AIAI - Post by User

NetraMark Holdings Inc

<< Previous

Bullboard Posts

Next >>

Post by StockHawk1on Mar 09, 2022 3:12pm

223 Views

Post# 34500544

$MEND CSO and Bioinformatics Director awarded

Yesterday, Nurosene Health Inc. ($MEND.C $MNNDF) announced its Chief Scientific Officer, Dr. Joseph Geraci and its Director of Bioinformatics Mike Tsay received the 'Highly Cited Paper' award from the journal, Exploration of Medicine.

Their research validates $MEND's AI platform and provides novel insights into Alzheimer's disease.

$MEND's technology is used to accelerate new drug discovery, to prevent clinical trial failure and help with biomarker identification.

https://ca.finance.yahoo.com/news/nurosenes-cso-director-bioinformatics-receives-153800849.html

$MEND is currently in the green @ $0.64

MC is $25.781M

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing